中文摘要：

目的探讨HCV 6型感染者的临床治疗方法。方法以聚乙二醇干扰素联合利巴韦林治疗HCV 6型感染者为试验组,治疗2/3型感染者为对照组,纳入病例必须完成治疗24周且随访时间达到24周以上。分析2组基本资料特征,比较2组病毒学应答效果。结果纳入HCV 6型感染者53例、2/3型感染者84例。HCV 6型、2/3型感染者获得RVR比例分别是88.7%、89.3%,率差95%可信区间为：（-0.113 9,0.101 9）;获得EVR的比例分别是94.3%、96.4%,率差95%可信区间为：（-0.095 0,0.053 0）;获得SVR的比例分别是86.8%、90.5%,率差95%可信区间为：（-0.147 6,0.073 6）;HCV 6型、2/3型感染者RVR对SVR的阳性预测值分别为89.4%、93.3%,率差95%可信区间为：（-0.143 6,0.065 6）;EVR对SVR的阳性预测值分别为88.0%、91.4%,率差95%可信区间为：（-0.142 8,0.074 8）。结论采用聚乙二醇干扰素联合利巴韦林治疗HCV 6型感染者的疗效非劣于2/3型感染者,故HCV 6型感染者推荐使用24周的标准联合抗病毒治疗方案。

英文摘要：

Objective To discuss the clinical treatment for patients infected with hepatitis C virus genotype 6（ HCV 6）. Methods Pegylated interferon plus ribavirin therapy for HCV 6 infection was defined as the experimental group,and the same therapy for HCV 2 /3 infection was defined as the control group. The therapy lasted for 24 weeks,and the follow-up time was more than 24 weeks. The basic data characteristics of the 2 groups were analyzed to compare their virological response effects. Results In the study,53 patients with HCV 6 infection and 84 patients with HCV 2 /3 infection were enrolled. The rapid virological response（ RVR） ratios of the patients infected with HCV 6 and HCV 2 /3 were 88. 7% and 89. 3%,respectively,and95% confidence interval was（- 0. 113 9,0. 101 9）. The early virological response（ EVR） ratios were94. 3% and 96. 4%,and 95% confidence interval was（- 0. 095 0,0. 053 0）. The sustained virological response（ SVR） ratios were 86. 8% and 90. 5%,and 95% confidence interval was（- 0. 147 6,0. 073 6）.The positive predictive values of RVR to SVR were 89. 4% and 93. 3%,and 95% confidence interval was（- 0. 143 6,0. 065 6）. The positive predictive values of EVR to SVR were 88. 0% and 91. 4%,and 95%confidence interval was（- 0. 142 8,0. 074 8）. Conclusion The curative effect of pegylated interferon plus ribavirin therapy for HCV 6 infection and HCV 2 /3 infection has no significant difference,so 24-week pegylated interferon plus ribavirin therapy is highly recommended to the patients infected with HCV 6.